पदोन्नति कार्यक्रम Reneo Pharmaceuticals, Inc.
उन्नत शेड्यूल
सरल ग्राफ
कंपनी के बारे में Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.IPO date | 2021-04-08 |
---|---|
ISIN | US75974E1038 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Сайт | https://reneopharma.com |
Цена ао | 1.82 |
प्रति दिन मूल्य परिवर्तन: | 0% (1.82) |
---|---|
प्रति सप्ताह मूल्य परिवर्तन: | 0% (1.82) |
प्रति माह मूल्य परिवर्तन: | 0% (1.82) |
3 महीने में कीमत में बदलाव: | 0% (1.82) |
छह महीने में कीमत में बदलाव: | +7.06% (1.7) |
प्रति वर्ष मूल्य परिवर्तन: | +9.64% (1.66) |
3 वर्षों में मूल्य परिवर्तन: | -47.85% (3.49) |
वर्ष की शुरुआत से मूल्य परिवर्तन: | 0% (1.82) |
|
बहुत मूल्यवान समझना
|
क्षमता
|
|||||||||||||||||||||||||||||||||||||
लाभांश
|
कर्तव्य
|
विकास का आवेग
|
संस्थानों | आयतन | शेयर करना, % |
---|---|---|
NEA Management Company, LLC | 4785494 | 14.32 |
Tang Capital Management, LLC | 3330000 | 9.96 |
Carlyle Group Inc. | 2698957 | 8.08 |
RiverVest Venture Management LLC | 2534220 | 7.58 |
Octagon Capital Advisors LP | 2250000 | 6.73 |
Bml Capital Management, LLC | 1314229 | 3.93 |
Highbridge Capital Management, LLC. | 1121704 | 3.36 |
Blackrock Inc. | 983304 | 2.94 |
Vanguard Group Inc | 978889 | 2.93 |
Aisling Capital Management LP | 886075 | 2.65 |
ETF | शेयर करना, % | वर्ष के लिए लाभप्रदता, % | लाभांश, % |
---|---|---|---|
iShares Micro-Cap ETF | 0.00768 | 17.09 | 1.54048 |
Principal Healthcare Innovators ETF | 0.00594 | 618.5 | 0.8416 |
Future Tech ETF | 0.00594 | 426.34 | 0.8416 |
Invesco Nasdaq Biotechnology ETF | 0.00486 | 28.58 | 0.8565 |
ProShares Ultra Nasdaq Biotechnology | 0.00333 | 51.7 | 0.85651 |
पर्यवेक्षक | नौकरी का शीर्षक | भुगतान | जन्म का साल |
---|---|---|---|
Mr. Michael G. Grey | Founder & Executive Chairman | 100k | 1953 (72 वर्ष) |
Mr. Gregory J. Flesher | President, CEO & Director | 569.7k | 1970 (55 साल) |
Mr. Michael P. Cruse | Chief Operating Officer | 535.47k | 1972 (53 वर्ष) |
Ms. Jennifer P. Lam | SVP of Finance & Administration and Principal Financial & Accounting Officer | N/A | |
Dr. Alejandro Dorenbaum M.D. | Chief Medical Officer | 466.23k | 1961 (64 वर्ष) |
पता: United States, Irvine. CA, 18575 Jamboree Road - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://reneopharma.com
वेबसाइट: https://reneopharma.com